Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, paroxetine's antihyperalgesic effect in a rat model of neuropathic pain was shown to be mediated by increased levels of the neurosteroid allopregnanolone in the spine.

This case report describes reversible hair loss in a patient taking aripiprazole, suggesting this side effect may be common among psychotropic medications.

This study found that cepharanthine may be a promising treatment for enterovirus infections, as it offered full protection to mice against lethal EV71 challenges and reduced viral titers and pathology.

This study introduces a novel pro-drug formulation of all-trans retinoic acid that reduces skin inflammation and achieves sustained drug release over several days compared to traditional methods.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

This case report describes two postmenopausal women with Parkinson's disease who experienced reversible hair loss after using the dopamine agonists pramipexole and ropinirole.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

This study reports that valproic acid is effective in treating absence seizures and shows improvement in other types of seizures, though about 20% of patients experienced adverse effects.

This study is the first to report that apremilast may be effective in treating refractory lichen planopilaris and frontal fibrosing alopecia, though some patients experienced adverse effects leading to discontinuation.

In this case report, a woman with ulcerative colitis experienced clinical deterioration during upadacitinib therapy, which improved after discontinuation, strongly suggesting drug hypersensitivity to the Janus kinase inhibitor as a potential cause for her symptoms.

This report describes five cases where sudden akathisia occurred in female patients with bipolar disorder after a ziprasidone dose reduction, emphasizing potential unexpected side effects of second-generation antipsychotics.

This article in the International Journal of Dermatology reports on a case series where the drug upadacitinib was used to treat patients with recalcitrant lichen planopilaris, but no abstract or detailed results are provided to assess its efficacy or safety fully.

In this case report, a 14-year-old girl developed azathioprine-induced anagen effluvium, highlighting it as a rare but reversible side effect with prompt drug withdrawal leading to significant hair regrowth.

This case report presents an instance of acute pancreatitis following the use of ocrelizumab and suggests that its B lymphocyte suppression may contribute to pancreatitis by affecting cytokine release and T lymphocyte regulation.

This article discusses the importance of raising awareness about specific adverse drug reactions, methods of prevention, and the significance of reporting them to the FDA's MedWatch program, but reports no new clinical results.

This case report found that a patient with ritlecitinib-resistant alopecia areata experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential effectiveness and suggesting benefits of personalized treatment strategies targeting the JAK1-mediated pathway.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.

This review examines the molecular mechanisms by which the proapoptotic protein ARTS inhibits tumorigenesis and discusses prospects for developing drugs that mimic its function, with no new experimental results reported.

This study found that combining the PAXMAN scalp cooling system with HairRepro MEDI α lotion led to a 50% success rate in reducing chemotherapy-induced alopecia and achieved complete hair regrowth by 3 months in Japanese breast cancer patients, suggesting enhanced efficacy over scalp cooling alone.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

This report highlights a case where a woman's use of the dopamine agonist pramipexole for Parkinson's disease was associated with hair loss, which improved after discontinuing the drug.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

This paper discusses anagen effluvium, a reversible non-scarring hair loss often triggered by certain chemotherapy drugs, but presents no new clinical results.

In this case study, a patient experienced darkening of hair color after taking acitretin, an oral retinoid known for potentially causing alopecia, marking a rare and undocumented phenomenon.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This article discusses the interest in folic acid antagonists for leukemia treatment, noting their potential mechanism of interfering with cellular growth, but reports no new clinical results.